Baert, T;
Ferrero, A;
Sehouli, J;
O Donnell, DM;
González-Martín, A;
Joly, F;
Van der Velden, J;
... Ledermann, JA; + view all
(2021)
The systemic treatment of recurrent ovarian cancer revisited.
Annals of Oncology
, 32
(6)
pp. 710-725.
10.1016/j.annonc.2021.02.015.
Preview |
Text
Ledermann_The Systemic Treatment of Recurrent Ovarian Cancer revisited_Pre-proof.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Treatment approaches for relapsed ovarian cancer have evolved over the past decade from a calendar-based decision tree to a patient-oriented biologically driven algorithm. Nowadays, platinum-based chemotherapy should be offered to all patients with a reasonable chance of responding to this therapy. The treatment-free interval for platinum is only one of many factors affecting patients' eligibility for platinum re-treatment. Bevacizumab increases the response to chemotherapy irrespective of the cytotoxic regimen and can be valuable in patients with an urgent need for symptom relief (e.g. pleural effusion, ascites). For patients with recurrent high-grade ovarian cancer, which responds to platinum-based treatment, maintenance therapy with a poly(ADP-ribose) polymerase inhibitor can be offered, regardless of the BRCA mutation status. Here we review contemporary decision-making processes in the systemic treatment of relapsed ovarian cancer.
Type: | Article |
---|---|
Title: | The systemic treatment of recurrent ovarian cancer revisited |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1016/j.annonc.2021.02.015 |
Publisher version: | https://doi.org/10.1016/j.annonc.2021.02.015 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Platinum retreatment, Platinum-based chemotherapy, Recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP) inhibitor |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre |
URI: | https://discovery.ucl.ac.uk/id/eprint/10124882 |
Archive Staff Only
View Item |